- Home
- NEE vs GILD Comparison
NEE vs GILD Comparison
Compare NEE & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEE
- GILD
- Stock Information
- Founded
- NEE 1925
- GILD 1987
- Country
- NEE United States
- GILD United States
- Employees
- NEE N/A
- GILD N/A
- Industry
- NEE Electric Utilities: Central
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NEE Utilities
- GILD Health Care
- Exchange
- NEE Nasdaq
- GILD Nasdaq
- Market Cap
- NEE 138.8B
- GILD 131.5B
- IPO Year
- NEE N/A
- GILD 1992
- Fundamental
- Price
- NEE $66.31
- GILD $104.54
- Analyst Decision
- NEE Buy
- GILD Buy
- Analyst Count
- NEE 14
- GILD 27
- Target Price
- NEE $85.29
- GILD $105.32
- AVG Volume (30 Days)
- NEE 12.9M
- GILD 10.4M
- Earning Date
- NEE 04-23-2025
- GILD 04-24-2025
- Dividend Yield
- NEE 3.42%
- GILD 3.02%
- EPS Growth
- NEE N/A
- GILD N/A
- EPS
- NEE 3.37
- GILD 0.38
- Revenue
- NEE $24,753,000,000.00
- GILD $28,754,000,000.00
- Revenue This Year
- NEE $17.98
- GILD $1.80
- Revenue Next Year
- NEE $8.29
- GILD $3.83
- P/E Ratio
- NEE $19.68
- GILD $275.11
- Revenue Growth
- NEE N/A
- GILD 6.04
- 52 Week Low
- NEE $61.72
- GILD $62.07
- 52 Week High
- NEE $86.10
- GILD $119.96
- Technical
- Relative Strength Index (RSI)
- NEE 43.09
- GILD 43.51
- Support Level
- NEE $65.30
- GILD $97.32
- Resistance Level
- NEE $68.44
- GILD $107.18
- Average True Range (ATR)
- NEE 2.58
- GILD 3.94
- MACD
- NEE -0.18
- GILD -0.45
- Stochastic Oscillator
- NEE 39.23
- GILD 41.42
About NEE NextEra Energy Inc.
NextEra Energy's regulated utility, Florida Power & Light, is the largest rate-regulated utility in Florida. The utility distributes power to nearly 6 million customer accounts in Florida and owns 34 gigawatts of generation. FP&L contributes roughly 70% of NextEra's consolidated operating earnings. NextEra Energy Resources, the renewable energy segment, generates and sells power throughout the United States and Canada with more than 34 GW of generation capacity, including natural gas, nuclear, wind, and solar.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).